Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors

Richard Elliott, Ashley Jarvis, Mohan Rajasekeran, Antony Oliver, Laurence Pearl, Christopher J Lord, Alan Ashworth, Caroline Springer

Research output: Contribution to journalArticlepeer-review

Abstract

The tankyrase proteins (TNKS, TNKS2), members of the PARP superfamily of enzymes, are attractive anti-cancer drug targets, particularly as inhibition of their catalytic activity has been shown to antagonise oncogenic WNT signalling. To identify chemical inhibitors of tankyrase we carried out an in silico small molecule screen using a set of ‘PARP-binding’ pharmacophores together with a generated (liganded) tankyrase homology model. This approach identified a structurally diverse set of ~1000 compounds for further study. Subsequent in vitro screening of recombinant tankyrase protein identified a subset of 59 confirmed inhibitors. Early optimisation followed by cell-based studies in WNT-dependent tumour cells, as well as co-crystallisation studies, identified a novel class of 3-aryl-5-substituted isoquinolin-1-ones, such as 21, that exhibit potent inhibition of tankyrase activity as well as growth inhibition of colorectal cancer cells.
Original languageEnglish
Pages (from-to)1687
Number of pages1692
JournalMedchemcomm
Volume6
Issue number9
DOIs
Publication statusPublished - 11 Aug 2015

Fingerprint

Dive into the research topics of 'Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors'. Together they form a unique fingerprint.

Cite this